Table 1. Clinical Demographics of the Four Patient Groups.
| Demographic | Healthy controls | Patients with HBV | Patients with HBsAg Seroclearance | Patients with HBV-associated HCC | P1 value a | P2 value b | P3 value c |
| No. of patients | 200 | 200 | 200 | 200 | |||
| Age, y | 43.04±14.54 (18.00–69.00) | 44.74±13.15 (18.00–69.00) | 51.57±13.29 (23.00–83.00) | 52.22±11.62 (19.00–82.00) | 0.199 | <0.001 | <0.001 |
| Sex (male %) | 87(44.0%) | 127(63.5%) | 109(54.5%) | 150(75.0%) | <0.001 | 0.084 | 0.017 |
| Albumin, g/dL | 42.98(3.1–54.9) | 45.10(20.5–52.1) | 45.2(21.7–54.4) | 41.35(21.3–49.9) | 0.048 | 0.055 | <0.001 |
| ALT, U/L | 18.00(4–186) | 28.00(6–1508) | 21.00(6–99) | 40.00(7–3513) | <0.001 | <0.001 | <0.001 |
| AST, U/L | 20.00(6–235) | 26.5(7–882) | 22.00(12–119) | 40.50(4–456) | <0.001 | <0.001 | <0.001 |
a
P1 value was calculated between HBV and healthy controls.
b
P2 value was calculated between HBV and HBsAg Seroclearance.
c
P3 value was calculated between HBV and HCC. P<0.05 was considered statistically significant.
Abbreviations: HBV, Hepatitis B virus; HCC, Hepatocellular Carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase.